According to the latest report by IMARC Group, “Global Renal Biomarkers Market Trends, Share, Growth, Industry Size, Opportunity and Forecast 2022-2027“, the global renal biomarkers market reached a value of US$ 1.13 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.88 Billion by 2027, exhibiting a CAGR of 8.70% during 2022-2027.
Renal biomarkers are the cells, proteins, microRNAs, genes, metabolites, proteomic patterns, lipids, etc., that are present on a urinalysis. They aid in determining the glomerular filtration rate (GFR) of kidneys in order to analyze their proper functioning and evaluate pathogenic processes and pharmacological responses to therapeutic interventions. Renal biomarkers also help in predicting disease progression and computing drug dosage. Consequently, they find extensive applications in hospitals and diagnostic laboratories across countries.
|Base Year: 2021|
|Forecast Year: 2022-2027|
Renal Biomarkers Market Trends and Drivers:
The increasing incidences of chronic kidney disease (CKD) and other non-communicable ailments, such as diabetes, hypertension, heart diseases, etc., are among the primary factors driving the renal biomarkers market. In addition to this, the growing need for blood urea nitrogen (BUN), urinary albumin, volume excretion, and serum creatinine (SCr) in the diagnosis and monitoring of CKD is further catalyzing the market growth.
Request Free Sample Report: https://www.imarcgroup.com/renal-biomarkers-market/requestsample
Moreover, the shifting preferences among healthcare professionals and researchers towards novel single biomarkers and process-specific biomarker panels are also augmenting the global market. In line with this, the inflating requirement to predict response to the treatment of acute kidney injury (AKI), glomerulopathies, autosomal dominant polycystic kidney disease (ADPKD), etc., is acting as another significant growth-inducing factor.
Furthermore, the integration of genomics, epigenetics, transcriptomics, proteomics, metabolomics, etc., is anticipated to fuel the renal biomarkers market over the forecasted period.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Renal Biomarkers Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG and Thermo Fisher Scientific Inc.
The report has segmented the market on the basis of region, type, diagnostic technique and end user.
Breakup by Type:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-regulated Protein
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Kidney Injury Molecule-1
Breakup by Diagnostic Technique:
- Enzyme-linked Immunosorbent Assay (ELISA)
- Particle-enhanced Turbidimetric Immunoassay (PETIA)
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Liquid Chromatography Mass Spectrometry (LC-MS)
Breakup by End User:
- Diagnostic Laboratory
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/renal-biomarkers-market
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
Key Questions Answered in This Report:
- What has been the impact of COVID-19 on the global renal biomarkers market?
- What are the key regional markets?
- How has the global renal biomarkers market performed so far and how will it perform in the coming years?
- What is the breakup of the market based on the biomarker type?
- What is the breakup of the market based on the diagnostic technique?
- What is the breakup of the market based on the end user?
- And, What are the various stages in the value chain of the industry?